Mogamulizumab-induced interface dermatitis drug rash treated successfully with methotrexate and extracorporeal photopheresis in a patient with Sézary syndrome

[1]  Ryanne A. Brown,et al.  Histopathologic Characterization of Mogamulizumab-associated Rash , 2020, The American journal of surgical pathology.

[2]  K. Carson,et al.  Mogamulizumab-Associated Cutaneous Granulomatous Drug Eruption Mimicking Mycosis Fungoides but Possibly Indicating Durable Clinical Response. , 2019, JAMA dermatology.

[3]  C. Elmets,et al.  Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. , 2018, The Lancet. Oncology.

[4]  D. Stroncek,et al.  Extracorporeal photopheresis as a therapy for autoimmune diseases , 2015, Journal of clinical apheresis.

[5]  M. Aljurf,et al.  Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation , 2014, Journal of transplantation.

[6]  M. Robin,et al.  Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  S. Iida,et al.  Stevens–Johnson Syndrome associated with mogamulizumab treatment of adult T‐cell leukemia / lymphoma , 2013, Cancer science.

[8]  M. Wasik,et al.  Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma. , 1998, Journal of the American Academy of Dermatology.